Dr. Paley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1000 Pines Lake Dr W
Wayne, NJ 07470Phone+1 516-817-1690- Is this information wrong?
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1987 - 1990
- Icahn School of Medicine at Mount SinaiResidency, Pediatrics, 1984 - 1987
- Ross University School of MedicineClass of 1984
- Yale UniversityB.A., Philosophy/Psychology
- New School for Social ResearchM.A., Psychology
Certifications & Licensure
- NJ State Medical License 2006 - 2025
- NY State Medical License 1987 - 2024
- CA State Medical License Active through 2014
Awards, Honors, & Recognition
- Top Doctors: New York Area Castle Connolly, 1999-2004
- Business Excellence Award Novartis Oncology, 2008
- President’s Award Novartis Oncology, 2006, 2009
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsJAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in ItalyAlessandro M. Vannucchi, Andrea Mortara, Andrea D’Alessio, Mara Morelli, Alberto Tedeschi, Moreno Festuccia, Antonella d'Arminio Monforte, Enrico Capochiani, Carmine S...> ;Journal of Clinical Medicine. 2021 Aug 23
- 8 citationsComparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk...Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al-Ali, Renato Tavares, Margherita Maffioli, Pia Raanani, Pilar Giraldo,...> ;Hematological Oncology. 2021 Jul 5
- 17 citationsAnalysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares, Haifa Kathrin Al-Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, C...> ;Leukemia & Lymphoma. 2021 Mar 21
- Join now to see all
Journal Articles
- The Palatability and Tolerability of Deferasirox Taken with Different Beverages or FoodsGoldberg SL, Giardina PJ, Chirnomas D. Esposito J, Paley C, Vichinsky E, Pediatric Blood Cancer, 9/1/2013
- Phase II Trial of Panobinostat, an Oral Pan-Deacetylase Inhibitor in Patients with Primary Myelofibrosis, Post-Essential Thrombocythaemia, and Post-Polycythaemia Vera ...Deangelo D, Mesa R, Fiskus W, Tefferi A. Paley C, Wadleigh M, Ritchie E, Snyder D, Degna K. Ganguly S, Ondovik M, Rine J, Bhalla K, Br J. Haematol, 5/23/2013
- Age-Related Treatment Patterns in Sickle Cell Disease Patients and the Associated Sickle Cell Complications and Healthcare CostsBlinder M, Vekeman F, Sasane M, Trahey A, Paley C, Duh M, Pediatric Blood Cancer, 5/1/2013
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Clinical Response by Baseline Characteristics in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma Treated with Panobinostat, Bortezomib, and Dexametha...Richardson P, Schlossman R, Alsina M, Coutre SE, Gasparetto C, Mukhopadhyay S. Ondovik M, Khan M, Paley C, Lonial S, ASCO, EHA, 1/1/2013
- PANORAMA 2: Panobinostat, Bortezomib, and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Myeloma - Poster PresentationRichardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gaspareto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley C, Lonial S, IMW, 1/1/2013
- PANORAMA 2: Panobinostat, combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma - Poster PresentationRichardson P, Alsina M, Weber DM, Coutre S, Lonial S, Gaspareto C, Mukhopadhyay S, Ondovik M, Khan M, Paley C, Schlossman R, ASH, 1/1/2012
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: